** Shares of genetic research equipment maker 10x Genomics TXG.O down 2.7% to $11.68 premarket
** Co sees 2025 revenue in the range of $610 million to $630 million, with midpoint below average of analyst's estimates of $622 million - LSEG data
** Posts Q4 loss of 40 cents per share compared to analyst's estimates of 29 cents per share
** "Despite the current uncertainty within U.S. academic research, we continue to have strong conviction in the large opportunity ahead" - CEO Serge Saxonov
** Brokerage Leerink Partners said on Monday that sales of companies such as TXG and Quanterix QTRX.O would be hit in Q1, as research centers and medical schools get cautious about purchasing equipment amid expected cost cuts of $4 billion at the National Institutes of Health
** In the last 12 months, TXG has fallen 74.3%
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.